摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-Acetylphenyl)-2-bromo-1-ethanone | 74754-40-8

中文名称
——
中文别名
——
英文名称
1-(4-Acetylphenyl)-2-bromo-1-ethanone
英文别名
1-(4-acetylphenyl)-2-bromoethanone
1-(4-Acetylphenyl)-2-bromo-1-ethanone化学式
CAS
74754-40-8
化学式
C10H9BrO2
mdl
——
分子量
241.084
InChiKey
KFADDSUIBUFMSD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    34.1
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-(4-Acetylphenyl)-2-bromo-1-ethanone 作用下, 以 1,4-二氧六环乙二醇二甲醚乙醚 为溶剂, 反应 97.0h, 生成 2-(4-Imidazo[1,2-a]pyrimidin-2-ylphenyl)imidazo[1,2-a]pyrimidine
    参考文献:
    名称:
    某些咪唑并[1,2-a]嘧啶衍生物的合成及抑菌活性。
    摘要:
    合成了75种咪唑并[1,2-a]嘧啶衍生物。据报道,这些化合物及其相应的α-溴代酮对多种革兰氏(+),革兰氏(-)细菌和分枝杆菌属物种具有“体外”抗菌活性。一些制备的衍生物表现出有效的抗微生物活性。
    DOI:
    10.1248/cpb.40.1170
  • 作为产物:
    描述:
    1,4-二乙酰苯 作用下, 以 1,4-二氧六环乙醚 为溶剂, 反应 1.0h, 生成 1-(4-Acetylphenyl)-2-bromo-1-ethanone
    参考文献:
    名称:
    某些咪唑并[1,2-a]嘧啶衍生物的合成及抑菌活性。
    摘要:
    合成了75种咪唑并[1,2-a]嘧啶衍生物。据报道,这些化合物及其相应的α-溴代酮对多种革兰氏(+),革兰氏(-)细菌和分枝杆菌属物种具有“体外”抗菌活性。一些制备的衍生物表现出有效的抗微生物活性。
    DOI:
    10.1248/cpb.40.1170
点击查看最新优质反应信息

文献信息

  • N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS
    申请人:Schmitz Ulrich Franz
    公开号:US20070265265A1
    公开(公告)日:2007-11-15
    Disclosed are compounds having Formula (I) and the compositions and methods thereof for treating or preventing a viral infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, R 2 , m, R, V, W, T, Z, R 1 , Y, and p are disclosed herein.
    揭示了具有Formula (I)的化合物,以及用于治疗或预防由Flaviviridae病毒家族中的病毒至少部分介导的病毒感染的组合物和方法,其中A、R2、m、R、V、W、T、Z、R1、Y和p在此处被揭示。
  • AMIDINE COMPOUND OR SALT THEREOF
    申请人:Tanikawa Tetsuya
    公开号:US20140155597A1
    公开(公告)日:2014-06-05
    The purpose of the present invention is to provide a novel compound which has an anti-fungal activity on pathogenic fungi including fungi belonging to the genus Candida , the genus Aspergillus and the genus Trichophyton and is useful as a medicinal agent. A compound represented by formula (I) (wherein A 1 represents a nitrogen atom or a group represented by formula CR 6 ; A 2 and A 3 are the same as or different from each other and independently represent a nitrogen atom or a group represented by formula CH; R 1 represents an aryl group which may be substituted by 1 to 5 substituents independently selected from a substituent group (2) or the like; R 2 and R 3 are the same as or different from each other and independently represent a hydrogen atom, a halogen atom, a C 1-6 alkyl group, a C 1-6 haloalkyl group or a C 1-6 alkoxy group; and R 4 and R 5 are the same as or different from each other and independently represent a hydrogen atom, a C 1-6 haloalkyl group, a C 1-6 alkyl group or the like) or a salt thereof is useful as an anti-fungal agent.
    本发明的目的是提供一种新颖的化合物,该化合物对包括属于念珠菌属、曲霉属和毛癣菌属的病原真菌具有抗真菌活性,并可用作药物。由公式(I) (其中A 1代表氮原子或由公式CR 6表示的基团;A 2和A 3相同或不同,独立地表示氮原子或由公式CH表示的基团;R 1表示可能由1至5个独立选自取代基组(2)的取代基取代的芳基;R 2和R 3相同或不同,独立地表示氢原子、卤素原子、C 1-6烷基、C 1-6卤代烷基或C 1-6烷氧基;R 4和R 5相同或不同,独立地表示氢原子、C 1-6卤代烷基、C 1-6烷基等)或其盐用作抗真菌剂。
  • [EN] PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDINONE ET DE PYRIMIDINONE COMME INHIBITEURS DU FACTEUR XIA
    申请人:ONO PHARMACEUTICAL CO
    公开号:WO2013093484A1
    公开(公告)日:2013-06-27
    The present invention provides compounds of the general formula (I), their salts and N- oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.
    本发明提供了一般式(I)的化合物,它们的盐和N-氧化物,以及它们的溶剂合物和前药(其中字符如描述中所定义)。一般式(I)的化合物是因子XIa的抑制剂,因此它们在预防和/或治疗血栓栓塞疾病方面是有用的。
  • Unraveling the Alkaline Phosphatase Inhibition, Anticancer, and Antileishmanial Potential of Coumarin-Triazolothiadiazine Hybrids: Design, Synthesis, and Molecular Docking Analysis
    作者:Aliya Ibrar、Sumera Zaib、Farukh Jabeen、Jamshed Iqbal、Aamer Saeed
    DOI:10.1002/ardp.201500392
    日期:2016.7
    (H‐157) cancer cell lines. Compound 5i showed highest cytotoxic potential against H‐157 cells with an IC50 value of 1.01 ± 0.12 μM, which is an improved inhibition compared to the standards (vincristine and cisplatin) used in this assay. Molecular docking studies were carried out on the synthesized library of coumarin–triazolothiadiazine hybrids against ALP. Almost all of the compounds showed strong interactions
    利用分子杂交概念设计并合成了一系列新的香豆素-三唑噻二嗪杂化化合物(5a-j)。环缩合反应涉及香豆素基 4-氨基-1,2,4-三唑和一系列溴苯乙酮,以良好的收率提供所需的产物。合成化合物的结构是在光谱分析数据的基础上建立的。制备的化合物针对碱性磷酸酶 (ALP) 进行了评估,其中在杂芳族核心的 3 位和 6 位结合双香豆素基序的化合物 5j 被证明是一种有效的抑制剂,IC50 值为 1.15 ± 1.0 µM。合成的化合物还针对主要利什曼原虫进行了测试,5h 是主要成员,IC50 值为 0.89 ± 0.08 μM。还使用肾成纤维细胞 (BHK-21) 和肺癌 (H-157) 癌细胞系测定了抗癌活性。化合物 5i 对 H-157 细胞显示出最高的细胞毒性潜力,IC50 值为 1.01 ± 0.12 μM,与该测定中使用的标准品(长春新碱和顺铂)相比,抑制作用得到改善。对针对 ALP 的香豆
  • Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
    申请人:——
    公开号:US20030225064A1
    公开(公告)日:2003-12-04
    This invention provides a compound of the formula: 1 or its pharmaceutically acceptable salt thereof, wherein A is partially unsaturated or unsaturated five membered heterocyclic, or partially unsaturated or unsaturated five membered carbocyclic, wherein the 4-(sulfonyl)phenyl and the 4-substituted phenyl in the formula (I) are attached to ring atoms of Ring A, which are adjacent to each other; R 1 is optionally substituted aryl or heteroaryl, with the proviso that when A is pyrazole, R 1 is heteroaryl; R 2 is C 1-4 alkyl, halo-substituted C 1-4 alkyl, C 1-4 alkylamino, C 1-4 dialkylamino or amino; R 3 , R 4 and R 5 are independently hydrogen, halo, C 1-4 alkyl, halo-substituted C 1-4 alkyl or the like; or two of R 3 , R 4 and R 5 are taken together with atoms to which they are attached and form a 4-7 membered ring; R 6 and R 7 are independently hydrogen, halo, C 1-4 alkyl, halo-substituted C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-4 alkylamino or N,N-di C 1-4 alkylamino; and m and n are independently 1, 2, 3 or 4. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.
    本发明提供了公式1的化合物或其药学上可接受的盐,其中A为部分不饱和或不饱和的五元杂环,或部分不饱和或不饱和的五元碳环,公式(I)中的4-(磺酰基)苯基和4-取代苯基连接到相邻的环A环原子上;R1为可选的取代芳基或杂芳基,但当A为吡唑时,R1为杂芳基;R2为C1-4烷基,卤代C1-4烷基,C1-4烷基氨基,C1-4双烷基氨基或氨基;R3、R4和R5独立地为氢、卤、C1-4烷基、卤代C1-4烷基或类似物,或者R3、R4和R5中的两个与它们连接的原子形成4-7成员环;R6和R7独立地为氢、卤、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、C1-4烷基硫基、C1-4烷基氨基或N,N-双C1-4烷基氨基;m和n独立地为1、2、3或4。本发明还提供了一种用于治疗前列腺素作为病原体涉及的医疗状况的药物组合物。
查看更多